RECCE-327

Recce noted that its phase 2 data “aligns with the FDA’s increased demand for novel broad-spectrum antibiotics to address antimicrobial resistance.”\n Recce Pharmaceuticals’ synthetic gel successfully treated a range of skin infections in a phase 2 trial, leading the Australian biotech to point to the anti-infective\'s potential to counter antimicrobial resistance, a growing global threat. A total of 27 out of the 29 evaluated patients (93%) who received the topical gel, dubbed R327G, for 14 days hit the primary efficacy endpoint in the trial, Recce said in a Feb. 19 release. The patients all had some form of acute bacterial skin and skin structure infections (ABSSSI), including some with diabetic foot infections.R327G was also shown to be safe and well tolerated, with no serious adverse events reported, hitting another of the study’s endpoints.“These impressive results underscore the potential of our topical gel to meet critical unmet medical needs in infection treatment,” Recce CEO James Graham said in the release. “As we advance towards registrational phase 3 trials in Indonesia and Australia, we are encouraged by the rapid efficacy and strong safety outcomes demonstrated in this study.” As well as diabetic foot infections, ABSSSIs can also include a flesh-eating infection called necrotizing fasciitis, and post-operative wound infections. The global market for these combined conditions is expected to reach $26 billion by 2032, according to Recce.Despite the growing threat of antibiotic resistance, whereby bacteria have evolved to evade older antibiotics meaning new ones need to be created, the low return on investment means many of the biggest biopharmas have given up working on new antifungals or antibiotics in recent years—although GSK in particular has continued to sign deals and post encouraging clinical results against infections like gonorrhea.In this morning’s release, Recce noted that its phase 2 data “aligns with the FDA’s increased demand for novel broad-spectrum antibiotics (such as R327G) to address antimicrobial resistance.” The Sydney, Australia-based biotech is pitching R327 as both an intravenous and topical therapy that can take on life-threatening infections from Gram-positive and Gram-negative bacteria, including in their superbug forms.Beyond R327, Recce’s pipeline of synthetic polymer anti-infectives also consists of R435 for bacterial infections and R529 for viral infections.“These results reflect the broad-spectrum nature and rapid onset of the effect of R327G, which positions us well for the upcoming phase 3 trials in Indonesia and Australia,” Recce’s Chief Medical Officer Alan Dunton, M.D., said in the release. “Importantly, Recce has also demonstrated that its R327 anti-infective compounds are effective in vitro against diverse species of bacteria, including over 500 clinical isolates, many of which were previously considered drug-resistant.”

Registrational Phase 3 trial for diabetic foot infections to be conducted across Indonesia, one of the world's largest diabetes patient populationsAwarded expedited regulatory review status in Indonesia to fast-track progression of Phase 3 trial, bringing forward commercial opportunities in ASEAN region SYDNEY, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), (Recce or the Company), the Company developing a new class of synthetic anti-infectives, today announced it has received approval from the Indonesian Drug and Food Regulatory Authority, Badan POM (BPOM), to initiate its registrational Phase 3 trial assessing RECCE® 327 as a topical gel (R327G) for the treatment of diabetic foot infections (DFIs). This significant milestone follows the recent human ethics committee approval to commence patient dosing, underscoring Recce’s clinical research's alignment with regulatory and ethical standards within Indonesia. With both approvals now secured, the Company remains on track to commence the registrational Phase 3 trial this quarter. These advancements are not only significant for the Company’s growth but also contribute positively to Indonesia's healthcare landscape by introducing potential novel treatments for infectious diseases, aligning with Recce’s commitment to addressing critical health challenges on an international scale. “The approval of Recce Pharmaceuticals' Phase 3 clinical trial is an important advancement in expanding treatment options for diabetic foot infections in Indonesia,” said Taruna Ikrar, MD, Ph.D., Chairperson of the Indonesian Food and Drug Authority (BPOM). “BPOM is committed to fostering the timely development of innovative therapies to address urgent health challenges. This collaboration reflects Indonesia’s mission to enhance healthcare outcomes for its population, and we are eager to see the trial’s impact on patients requiring effective, novel anti-infective treatments.” With over 19.5 million adults living with diabetes in Indonesia,1 the need for innovative therapies to address diabetes-related infections, such as foot infections, urinary tract infections, and surgical site infections, is urgent. As a Registrational Phase 3 clinical trial for DFIs, this is one of the largest DFI studies in the world,2 and the first of its kind across Indonesia. The trial will be conducted as a double-blinded, placebo-controlled study evaluating R327G for the treatment of DFIs and is on track to begin mid-December and aims to enroll up to 300 patients (200 to receive R327G and 100 to receive placebo). The trial will run for approximately 12 months, with an expected read-out in late 2025 and expected regulatory approval and commercial launch in H1 CY26. The study is made possible thanks to the significant support of key Indonesian stakeholders, including the Indonesian Ministry of Health, Badan POM, PT Etana Biotechnologies, and the Australian Government, accelerating R327G’s path to commercialization. The study will cost Recce around $2M before further subsiding by the Australian government’s 43.5% R&D rebate scheme under the Company’s Advanced Overseas Advanced Finding status with AusIndustry. All intellectual property is that of Recce. On a local front, with the Phase 2 acute bacterial skin and skin structure infections (ABSSSI) trial in the final stages and on track to finish this calendar year, Recce is expected to initiate a Phase 3 registrational study of R327G in Australia in H1 2025, with a parallel program across the ASEAN focused initially on DFIs allowing an expansive international strategy, bringing near-term revenue opportunities of ASEAN to the forefront. James Graham, Chief Executive Officer of Recce Pharmaceuticals, added, “The approval from the Indonesian National Drug and Food Authority to initiate this pivotal Phase 3 trial in Recce’s clinical development is a significant achievement, bringing Recce closer to commercialization and profitability. We also acknowledge the support of Investment NSW, Austrade, and the Australian Embassy team in Jakarta, which played an important role in helping with the approval process. We look forward to evaluating R327G in our first Phase 3 trial.” About Recce Pharmaceuticals LtdRecce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) is developing a New Class of Synthetic Anti-Infectives designed to address the urgent global health problems of antibiotic-resistant superbugs and emerging viral pathogens. Recce’s anti-infective pipeline includes three patented, broad-spectrum, synthetic polymer anti-infectives: RECCE® 327 (R327) as an intravenous and topical therapy that is being developed for the treatment of serious and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria, including their superbug forms; RECCE® 435 (R435) as an orally administered therapy for bacterial infections; and RECCE® 529 (R529) for viral infections. Through their multi-layered mechanisms of action, Recce’s anti-infectives have the potential to overcome the processes utilised by bacteria and viruses to overcome resistance – a current challenge facing existing antibiotics. The World Health Organization (WHO) added R327, R435, and R529 to its list of antibacterial products in clinical development for priority pathogens, recognising Recce’s efforts to combat antimicrobial resistance. The FDA granted R327 Qualified Infectious Disease Product designation under the Generating Antibiotic Initiatives Now (GAIN) Act, providing Fast Track Designation and 10 years of market exclusivity post approval. R327 is also included on The Pew Charitable Trusts’ Global New Antibiotics in Development Pipeline as the sole synthetic polymer and sepsis drug candidate in development. Recce wholly owns its automated manufacturing, supporting current clinical trials. Recce’s anti-infective pipeline aims to address synergistic, unmet medical needs by leveraging its unique technologies. Corporate ContactJames GrahamRecce Pharmaceuticals Ltd+61 (02) 9256 2571James.graham@recce.com.au Media & Investor Relations (AU)Andrew GeddesSeed Media+61 (02) 9267 4511andrew@seedmedia.com.au Media (USA)Michael FitzhughLifeSci Communicationsmfitzhugh@lifescicomms.com Investor Relations (USA & EU)Guillame van RenterghemLifeSci Advisorsgvanrenterghem@lifesciadvisors.com 1 https://idf.org/our-network/regions-and-members/western-pacific/members/indonesia/2 https://www-ncbi-nlm-nih-gov.libproxy1.nus.edu.sg/pmc/articles/PMC8351150/